Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06836063 is Phase 2b, active not recruiting, with enrollment complete Dec 2025. Topline results expected May-Jun 2026 per sponsor updates. No public readout available as of Apr 2026; trial ongoing.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial (NCT06836063, Phase 2b Ropanicant in MDD) is active/not recruiting with primary completion Feb 2026 and topline expected May/July 2026. No efficacy readout or results available yet. Prior open-label Phase 2a was positive but is a different study.
Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed92% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public efficacy readout is found yet. Sponsor said NCT06836063 topline efficacy/safety data were anticipated in May 2026, and trial-tracking sources still describe the study as ongoing with no results posted. That is insufficient to call the Phase 2 readout positive or negative.
Found Apr 3, 2026, 4:08 PMReviewed Apr 3, 2026, 4:47 PM
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout is public yet for NCT06836063. The sponsor’s latest cited update says last patient out was expected by end-February 2026 and topline efficacy/safety results are anticipated in May 2026. Sponsor news listings also show only enrollment milestones for this Phase 2b trial, not outcomes.
Found Apr 1, 2026, 7:15 PMReviewed Apr 1, 2026, 7:16 PM